JP2018523683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523683A5 JP2018523683A5 JP2018508683A JP2018508683A JP2018523683A5 JP 2018523683 A5 JP2018523683 A5 JP 2018523683A5 JP 2018508683 A JP2018508683 A JP 2018508683A JP 2018508683 A JP2018508683 A JP 2018508683A JP 2018523683 A5 JP2018523683 A5 JP 2018523683A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- muscle
- state
- loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 210000003205 muscle Anatomy 0.000 claims 14
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 5
- 229940049953 phenylacetate Drugs 0.000 claims 5
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 5
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 229950009215 phenylbutanoic acid Drugs 0.000 claims 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 3
- 229960003104 ornithine Drugs 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 229960004203 carnitine Drugs 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 claims 1
- VVJYUAYZJAKGRQ-UHFFFAOYSA-N 1-[4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C(O)C1 VVJYUAYZJAKGRQ-UHFFFAOYSA-N 0.000 claims 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 1
- 108010082126 Alanine transaminase Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000005153 frontal cortex Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001243 protein synthesis Methods 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 229940006198 sodium phenylacetate Drugs 0.000 claims 1
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206466P | 2015-08-18 | 2015-08-18 | |
| US62/206,466 | 2015-08-18 | ||
| PCT/US2016/047211 WO2017031131A1 (en) | 2015-08-18 | 2016-08-16 | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523683A JP2018523683A (ja) | 2018-08-23 |
| JP2018523683A5 true JP2018523683A5 (https=) | 2019-09-26 |
| JP6990170B2 JP6990170B2 (ja) | 2022-01-12 |
Family
ID=58051237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508683A Active JP6990170B2 (ja) | 2015-08-18 | 2016-08-16 | Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10835506B2 (https=) |
| EP (1) | EP3337473A4 (https=) |
| JP (1) | JP6990170B2 (https=) |
| AU (1) | AU2016308641B2 (https=) |
| CA (1) | CA2995823A1 (https=) |
| HK (1) | HK1249434A1 (https=) |
| WO (1) | WO2017031131A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035921T2 (en) | 2009-04-03 | 2018-05-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| CN104434894A (zh) | 2009-06-08 | 2015-03-25 | Ucl商业有限公司 | 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能 |
| ES2769000T3 (es) | 2014-11-24 | 2020-06-24 | Ucl Business Ltd | Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco |
| CN108366983A (zh) * | 2015-11-13 | 2018-08-03 | 欧塞拉治疗有限公司 | L-鸟氨酸苯乙酸盐制剂 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| MX389665B (es) | 2017-05-11 | 2025-03-20 | Ocera Therapeutics Inc | Procesos para producir fenilacetato de l-ornitina |
| MX2020001765A (es) | 2017-08-14 | 2020-07-29 | Axcella Health Inc | Composiciones de aminoacidos para el tratamiento de enfermedad hepatica. |
| JP2019214546A (ja) * | 2018-06-11 | 2019-12-19 | 学校法人福岡大学 | 終末糖化産物生成抑制剤及び医薬組成物 |
| CN112839643A (zh) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
| SG11202111509PA (en) | 2019-05-09 | 2021-11-29 | Ocera Therapeutics Inc | Methods of assessing and treating hepatic encephalopathy |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (https=) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| FR2113774A1 (en) | 1970-11-13 | 1972-06-30 | Roques Ets | Prepn of l-ornithine salts with org acids - using silver oxides |
| US4100293A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US4857555A (en) * | 1985-09-12 | 1989-08-15 | Brigham & Women's Hospital | Method of treating catabolic dysfunction |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US5139981A (en) | 1987-06-24 | 1992-08-18 | Union Carbide Chemicals & Plastics Technology Corporation | Process for preparing silver(I)-exchanged resins |
| DE4020980C1 (https=) | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US5840891A (en) | 1994-07-28 | 1998-11-24 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative |
| IL116674A (en) | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| WO1997030167A1 (en) | 1996-02-13 | 1997-08-21 | The Trustees Of The University Of Pennsylvania | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| CA2374273A1 (en) | 1999-05-21 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Liver function controlling agents |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| JPWO2002074302A1 (ja) | 2001-03-15 | 2005-07-14 | 独立行政法人理化学研究所 | 肝機能障害改善用アミノ酸組成物 |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| JPWO2004019928A1 (ja) | 2002-08-30 | 2005-12-15 | 味の素株式会社 | 肝疾患治療剤 |
| US20050059150A1 (en) | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7589235B2 (en) | 2004-05-06 | 2009-09-15 | Osteologix, A/S | High yield and rapid synthesis methods for producing metallo-organic salts |
| WO2006059237A1 (en) | 2004-08-30 | 2006-06-08 | Lunamed, Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| GB0426141D0 (en) | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| SI2153870T1 (sl) | 2004-11-26 | 2014-05-30 | Ucl Business Plc | Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije |
| JPWO2007077995A1 (ja) | 2006-01-05 | 2009-06-11 | 協和発酵バイオ株式会社 | 筋肉増量剤 |
| WO2009149196A1 (en) * | 2008-06-04 | 2009-12-10 | Phenolics, Llc. | Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same |
| HUE035921T2 (en) | 2009-04-03 | 2018-05-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| CA2763894A1 (en) | 2009-06-02 | 2011-01-13 | Salix Pharmaceuticals, Ltd. | Use of rifaximin to maintain remission of hepatic encephalopathy |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| CN104434894A (zh) | 2009-06-08 | 2015-03-25 | Ucl商业有限公司 | 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能 |
| US8946473B2 (en) | 2010-10-06 | 2015-02-03 | Ocera Therapeutics, Inc. | Methods of making L-ornithine phenyl acetate |
| PT2922576T (pt) | 2012-11-21 | 2018-01-24 | Horizon Therapeutics Llc | Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática |
| ES2769000T3 (es) | 2014-11-24 | 2020-06-24 | Ucl Business Ltd | Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco |
| CN107708684A (zh) | 2015-04-20 | 2018-02-16 | 欧塞拉治疗有限公司 | L‑鸟氨酸苯乙酸盐制剂 |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
-
2016
- 2016-08-16 WO PCT/US2016/047211 patent/WO2017031131A1/en not_active Ceased
- 2016-08-16 US US15/750,009 patent/US10835506B2/en active Active
- 2016-08-16 HK HK18109080.2A patent/HK1249434A1/zh unknown
- 2016-08-16 JP JP2018508683A patent/JP6990170B2/ja active Active
- 2016-08-16 AU AU2016308641A patent/AU2016308641B2/en active Active
- 2016-08-16 EP EP16837708.3A patent/EP3337473A4/en not_active Withdrawn
- 2016-08-16 CA CA2995823A patent/CA2995823A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523683A5 (https=) | ||
| RU2491062C2 (ru) | Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий | |
| RU2008143310A (ru) | Способы лечения с применением цитруллина | |
| RU2016147575A (ru) | Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции | |
| RU2015145255A (ru) | Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы | |
| JP2004352696A (ja) | アミノ酸組成物及び補液 | |
| JP2018531929A5 (https=) | ||
| EP2875736B1 (en) | N-Carbamoylputrescine to enhance muscle protein synthesis | |
| RU2019110150A (ru) | Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции | |
| JP2021527670A5 (https=) | ||
| BR112015030767B1 (pt) | Uso de uma composição | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2009534360A (ja) | アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用 | |
| JP2019529569A5 (https=) | ||
| CA2565993A1 (en) | Salt of 4-or 5- aminosalicylic acid | |
| JP3937423B2 (ja) | アミノ酸含有アルブミン製剤 | |
| JPWO2000043035A1 (ja) | アミノ酸含有アルブミン製剤 | |
| JP6926192B2 (ja) | Ｎ，ｎ−ビス−２−メルカプトエチルイソフタルアミドの新規用途 | |
| JP5775096B2 (ja) | インフルエンザの治療剤または予防剤 | |
| RU2302239C1 (ru) | Способ фармакологической коррекции ишемии конечности | |
| CN102698250A (zh) | 一种酒精肝、脂肪肝的注射针剂 | |
| WO1999016433A1 (en) | Remedy for hepatopathy | |
| JP6100510B2 (ja) | 抗感冒剤 | |
| JP2025505187A5 (https=) | ||
| JP7264169B2 (ja) | 間欠的持久力向上剤または血中ｐＨ上昇剤 |